Press release MHRA approves GLP –1 receptor agonist semaglutide to lower chance of great heart problems in obese or overweight adults Semaglutide is the 1st weightloss drug authorised in the united kingdom as being a preventative treatment for the people with established cardiovascular diseaseWegovy® is a weight reduction drug containing the Ene